Why Is Nutraceuticals Player Cosmos Health Stock Trading Higher Today?

Cosmos Health Inc (NASDAQ: COSM) announced its inaugural 2026 revenue and 

Cosmos Health Inc (NASDAQ:COSM) announced its inaugural 2026 revenue and EBITDA guidance.

The company forecasts over $180 million in gross annual revenue, with EBITDA in excess of $20 million.

Greg Siokas, CEO of Cosmos Health, stated: “We are pleased to announce guidance based on our long-term outlook to achieve substantial growth and profitability…This projection has been carefully formulated, taking into account several factors. Notably, we have a clear view of our existing logistics distribution businesses, which consistently generate stable cash flows.” 

“Additionally, revenue is expected to be augmented by bolt-on acquisitions, which would expand our distribution network, leading to growth in accretive cash flows. Furthermore, strategic acquisitions such as Cana will play a pivotal role,” Siokas added.

In August, Cosmos Health reported Q2 revenues of $12.36 million, down 6.4% Y/Y. The company reported adjusted EPS of $0.01, compared to a $(0.35) loss in the prior year. 

Price Action: COSM shares are up 16.20% at $1.15 on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

U.S. FDA Approves Bristol Myers Squibb And 2seventy bio’s Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 Ka…

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profileExpanded approval

BMY